Cohance Lifesciences opened higher at ₹447.50, compared with its previous close of ₹444.45. During today's session, the stock has traded between ₹427.50 and ₹447.70, with an average traded price of ₹434.75. It is currently showing a downward intraday trend.
An investment of ₹10,000 made 5 years ago in Cohance Lifesciences is now worth
₹ 8,195.00
resulting in a loss of
₹ 1,805.00 (18.05%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
-7.10 (-1.60%)
Day High
₹447.70
Day Low
₹427.50
Day Open
₹447.50
Prev Close
₹444.45
Volume
4,35,818
Value Traded
₹18.95 Cr
1W Return
-2.12%
1M Return
-0.65%
3M Return
-3.22%
6M Return
15.73%
1Y Return
-51.66%
Market Cap (₹ Cr.)
16,733
PE Ratio
290.60
PB Ratio
4.35
Dividend Yield
1.35%
ROE
3.72%
ROCE
4.81%
Book Value (₹)
102.23
Face Value (₹)
1.00
EPS (TTM)
-0.63
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
-2.12%
6 Week
-
1 Month
-0.65%
3 Month
-3.22%
9 Month
-4.38%
Cohance Lifesciences receives central government approval for Umang Vohra
Ministry of Corporate Affairs approved Umang Vohra as Chairman and Group CEO. Approval letter dated October 8, 2026, received by company on October 12, 2026. Appointment follows prior intimations to exchanges in April and June 2026. Cohance Lifesciences was formerly known as Suven Pharmaceuticals Limited.
YesterdayCohance Lifesciences receives voluntary 'Strong' ESG rating from Crisil
Cohance Lifesciences received a voluntary ESG rating of "Crisil ESG 61 (Strong)". Crisil also assigned a Core ESG Rating of "Crisil Core ESG 67 (Strong)". The rating was independently determined using publicly available information. Cohance stated it did not engage Crisil for the assessment.
7 days agoCohance Lifesciences Jaggaiahpet API facility clears USFDA inspection
Cohance Lifesciences' Jaggaiahpet API facility underwent a USFDA inspection. The inspection concluded with five observations noted by the USFDA. Facilities receiving observations are typically required to submit a written response to the agency.
22 days agoCohance Lifesciences remits USD 10 million for NJ Bio CCPS subscription
Cohance Lifesciences remitted USD 10 million for NJ Bio CCPS. Investment supports growth in ADC CRDMO capabilities. NJ Bio turnover fell to USD 23.5 million in CY2025 from USD 32.6 million in CY2024. Transaction complies with FEMA Overseas Investment Regulations 2022.
25 days agoCohance Lifesciences passes all AGM resolutions including director reappointment
Cohance Lifesciences passed all three ordinary resolutions at its 8th AGM held on September 17, 2026. Shareholders approved the adoption of standalone and consolidated financial statements for FY26. Ms. Shweta Jalan was reappointed as a director liable to retire by rotation. Total votes polled stood at 317,125,944 shares, representing 82.89% participation.
26 days agoCohance Lifesciences to host investor meets in Mumbai, Hyderabad
Cohance Lifesciences hosts JP Morgan India Conference meet in Mumbai on September 22, 2026. Management to attend JP Morgan Roadshow in Hyderabad on September 24, 2026. Interactions include both group and one-on-one sessions with analysts. Schedule subject to change; no unpublished price-sensitive info to be shared.
26 days ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,770.70 | +0.61% | ₹4,24,850.24 | 34.83 | +5.97% | |
| ₹9,285.00 | -1.50% | ₹2,46,487.58 | 85.12 | +43.41% | |
| ₹4,642.90 | -0.84% | ₹1,76,600.99 | 82.55 | +31.42% | |
| ₹1,132.50 | -0.17% | ₹1,12,967.31 | 24.74 | +14.00% | |
| ₹2,059.40 | -0.47% | ₹1,11,271.90 | 102.63 | +134.89% | |
| ₹1,329.60 | +1.40% | ₹1,07,412.86 | 31.62 | -14.87% | |
| ₹1,240.00 | +0.86% | ₹1,03,500.36 | 32.26 | -1.93% | |
| ₹2,372.00 | -1.17% | ₹97,974.30 | 47.92 | -3.57% | |
| ₹1,684.60 | -1.31% | ₹96,928.16 | 26.40 | +49.04% | |
| ₹1,953.60 | +0.96% | ₹89,336.17 | 16.03 | -0.29% | |
| ₹2,265.30 | -0.78% | ₹63,932.35 | 35.82 | +16.81% | |
| ₹5,250.00 | +0.86% | ₹62,771.63 | 28.34 | -3.75% |
An investment of ₹10,000 made 5 years ago in Cohance Lifesciences is now worth
₹ 8,195.00
resulting in a loss of
₹ 1,805.00 (18.05%)
Note: Past profits do not guarantee future returns.
